– USA, CA – Bluejay Therapeutics, a clinical-stage biopharmaceutical company rapidly progressing transformative therapies for viral hepatitis and other serious liver diseases, announced the additions of Eric Dobmeier and Dan Spiegelman to its board of directors.
About Eric Dobmeier
Eric Dobmeier, Lead Independent Director, is the former President and CEO of Chinook Therapeutics and Silverback Therapeutics. Before that, he spent 15 years at Seagen, where he served as COO. He serves on the boards for Structure Therapeutics, Janux Therapeutics, and several other private biotechnology companies. He is also a venture partner for Samsara BioCapital.
Eric Dobmeier holds a J.D. from the University of California Berkeley School of Law and an undergraduate degree from Princeton University.
About Dan Spiegelman
Dan Spiegelman, Chair of the Audit Committee, is the former CFO of BioMarin Pharmaceutical and CV Therapeutics, and former Treasurer at Genentech. Spiegelman co-founded Rapidscan Pharma Solutions, which was sold to GE Healthcare. He is also a venture partner for Samsara BioCapital. He serves on the board of directors for Kyverna Therapeutics, Spruce Biosciences, vTv Therapeutics, Maze Therapeutics, and Tizona Therapeutics.
Dan Spiegelman holds an MBA from the Stanford Graduate School of Business and a bachelor’s degree from Stanford University.
About Bluejay Therapeutics
Bluejay Therapeutics is a clinical-stage biopharmaceutical company focused on the development of potentially life-changing treatments for viral hepatitis and liver diseases. The company is currently investigating BJT-778 for the treatment of chronic hepatitis D and chronic hepatitis B. Additionally, Bluejay is advancing several innovative programs to find a combination regimen to achieve a functional cure for chronic hepatitis B, including a proprietary TLR9 agonist (cavrotolimod) and a liver-targeted hepatitis B virus (HBV) transcript inhibitor (BJT-628).
For more information: https://bluejaytx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.